{"Name":"Raphael Chow","Level":"アソシエイト","ExceptionLanguage":"","PracticesPreviewOverride":"","ExtensionceAttorneyExperience":"

Recent examples of Raphael’s work include advising:

ADVANZ PHARMA, a Nordic Capital portfolio company, in connection with the issuance of €917 million (equivalent) in new euro- and pound sterling-denominated senior secured notes and the borrowing of a €165 million term loan B facility.

","ExtensionceAttorneyProBono":"","MembershipsAndAffiliations":"","CredentialsOverride":"","AdmissionsOverride":"","MobileExperienceHeader":"代表案件","MobileExperienceNext":"代表案件","PublicationLabel":"著書","EventLabel":"イベント","NewsLabel":"ニュース","NewsletterLabel":"Newsletters","StoryLabel":"ストーリー","RichTextAreasModule":{"RichTextAreas":[{"Title":"","Overview":"","OverviewExpanded":"

RAPHAEL CHOW advises clients on a variety of cross-border debt finance transactions, including private equity sponsors, funds, corporations, and financial institutions.

Raphael was trained at a magic circle firm in Hong Kong and London, where he gained experience in investment-grade lending, structured and securitised finance, mergers and acquisitions and equity capital markets. Before joining Sidley, Raphael spent time with another U.S. headquartered law firm in London.

Raphael is fluent in English, Cantonese and Mandarin.

*Only admitted to practice in Hong Kong. Not admitted to practice in England and Wales.

","OverviewReadMoreLabel":"More","OverviewViewLessLabel":"Less"}],"CssClass":null,"FolderTemplateID":null,"SiteImproveReadMoreDataAttributes":""},"RelatedArticles":{"ResultCount":1,"HasMoreResults":false,"GridData":[{"ID":"4ee11c61-f254-41a2-b02f-27416ef08519","ContentType":"お知らせ","DisplayDate":"April 10, 2025","Title":"Sidley Advises ADVANZ PHARMA on €1.08 Billion (Equivalent) Refinancing","ShortTitle":"","Summary":"","Source":"","Location":null,"Tags":null,"NavigateLink":{"ViewUrls":[{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"itlang","CurrentViewID":null,"Name":null,"Url":"/it/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"itlang","CurrentViewID":null,"Name":null,"Url":"/it/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"kolang","CurrentViewID":null,"Name":null,"Url":"/ko/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"kolang","CurrentViewID":null,"Name":null,"Url":"/ko/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"pllang","CurrentViewID":null,"Name":null,"Url":"/pl/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"pllang","CurrentViewID":null,"Name":null,"Url":"/pl/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"hilang","CurrentViewID":null,"Name":null,"Url":"/hi/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"hilang","CurrentViewID":null,"Name":null,"Url":"/hi/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"jalang","CurrentViewID":null,"Name":null,"Url":"/ja/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"jalang","CurrentViewID":null,"Name":null,"Url":"/ja/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"bglang","CurrentViewID":null,"Name":null,"Url":"/bg/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"bglang","CurrentViewID":null,"Name":null,"Url":"/bg/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"ptlang","CurrentViewID":null,"Name":null,"Url":"/pt/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"ptlang","CurrentViewID":null,"Name":null,"Url":"/pt/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"idlang","CurrentViewID":null,"Name":null,"Url":"/id/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"idlang","CurrentViewID":null,"Name":null,"Url":"/id/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"zhlang","CurrentViewID":null,"Name":null,"Url":"/zh-hans/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"zhlang","CurrentViewID":null,"Name":null,"Url":"/zh-hans/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"delang","CurrentViewID":null,"Name":null,"Url":"/de/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"delang","CurrentViewID":null,"Name":null,"Url":"/de/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"nllang","CurrentViewID":null,"Name":null,"Url":"/nl-nl/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"nllang","CurrentViewID":null,"Name":null,"Url":"/nl-nl/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"frlang","CurrentViewID":null,"Name":null,"Url":"/fr/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"frlang","CurrentViewID":null,"Name":null,"Url":"/fr/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"rulang","CurrentViewID":null,"Name":null,"Url":"/ru/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"rulang","CurrentViewID":null,"Name":null,"Url":"/ru/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"eslang","CurrentViewID":null,"Name":null,"Url":"/es/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"eslang","CurrentViewID":null,"Name":null,"Url":"/es/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"83e3dcaa-1264-4226-8ee6-380c20e95bea","Language":"enlang","CurrentViewID":null,"Name":null,"Url":"/en/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"},{"ID":"95a638d2-4bab-4290-a874-f1c9e30c33b9","Language":"enlang","CurrentViewID":null,"Name":null,"Url":"/en/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing"}],"Url":"/en/newslanding/newsannouncements/2025/04/sidley-advises-advanz-pharma-on-1-billion-equivalent-refinancing","Title":"Sidley Advises ADVANZ PHARMA on €1.08 Billion (Equivalent) Refinancing","Target":"_self","CssClass":"","Language":"","IsActive":false,"IsExternal":false,"Children":null},"TemplateID":"c7ca4050-a9f3-4e7c-a3cc-0277d1cfb7eb"}],"UpcomingEvents":[],"SearchFilters":{"CurrentViewID":"957999b3-455b-43de-a2cb-f8856c9b68cf","Skip":0,"Take":4,"InitialPageSize":4,"ReloadFilters":false,"SeparateUpcomingEvents":false,"CurrentDayEventsOnly":false,"UpcomingEventsOnly":false,"IsBioOnly":true,"DateFrom":null,"DateTo":null,"KeywordFilter":"","PinnedItems":"","ExcludedPinnedItems":"","UsePinnedItems":true,"SortField":0,"PracticeFilters":[],"IndustryFilters":[],"TypeFilters":[],"MediaFilters":null,"EventTypeFilters":[],"ArticleTypeFilters":[{"RichTextContent":"","PinnedItems":"","DisplaySearchResultListing":true,"IsResources":false,"IsMedia":false,"ID":"dbb4c9d1-b36c-4588-b283-e8407fc49c7d","Name":"ニュース","Title":null,"Url":"","IsSelected":true,"IsEnabled":true,"Filter":[]}],"DateFilters":[],"TopicFilters":[],"BlogFilters":[],"OtherFilters":[{"ID":"abda8509-0196-4993-836b-d0c19c7f6ea6","Name":null,"Title":null,"Url":null,"IsSelected":true,"IsEnabled":true,"Filter":[]}],"ProBonoFilters":[],"SingleResultLabel":null,"MultipleResultLabel":null},"ShowSection":true,"Query":null,"MediaViewModel":null,"FeaturedHeader":null,"FeaturedSubHeader":null},"PublicationOverride":null,"EventOverride":null,"RepresentativeMattersDefaultClass":null,"ProBonoDefaultClass":null,"MembershipDefaultClass":null,"DisclaimerNotAdmittedToPractice":"*Only admitted to practice in Hong Kong. Not admitted to practice in England and Wales.","HasCallToActions":false,"HasAdditionalDetail":true,"IsOneTab":true,"OneTabCss":"one-tab"}

弁護士資格・登録

学歴